Objectives: Ultrasmall particles of iron oxide (USPIO) possess superparamagnetic properties and are used as negative contrast agent in magnetic resonance imaging (MRI) because of their strong T 2 and T 2 * effects. Besides this method, electron paramagnetic resonance (EPR) offers the unique capability to quantify these particles. The objective of this study was to evaluate a molecular marker for non invasive diagnosis and monitoring of inflammation. During inflammation cell adhesion molecules such as Eselectin are expressed on the endothelial cell surface. An E-selectin ligand was coupled to pegylated USPIO particles. Materials and Methods: Inflammation was induced by intramuscular injection of Freund's Complete Adjuvant in male NMRI mice. After intravenous injection of grafted or ungrafted USPIO particles, iron concentration in inflamed muscles was quantified ex vivo by X-band EPR. Particle accumulation was also assessed in vivo by L-Band EPR, as well as by T 2 -weighted MRI. Results: We determined the mean iron oxide concentration in inflamed muscles after injection of grafted or ungrafted UPSIO particles, which was 0.8% and 0.4% of the initially injected dose, respectively. By L-band EPR, we observed that the concentration of the grafted USPIO particles in inflamed muscles was twice higher than for the ungrafted particles. Using MRI experiments, a higher signal loss was clearly observed in the inflamed muscle when grafted particles were injected in comparison with the ungrafted particles. Conclusion: Even taking into account a non specific accumulation of iron oxides, the targeting of USPIO particles with E-selectin ligands significantly improved the sensitivity of detection of inflamed tissues.
M olecular markers of inflammation are needed to be able to diagnose and monitor inflammation in a noninvasive manner before the occurrence of irreversible anatomic changes. 1 Physical examination is often subjective and serum markers of inflammation do not provide information about the localization of the inflamed zone. 2 Molecular markers for imaging could, therefore, be helpful in diseases where the inflammatory action of misdirected leukocytes can destroy healthy tissues, such as in atherosclerotic plaques, 3 graft rejection, 4 ischemia-reperfusion injury, 5 multiple sclerosis, 6 and rheumatoid arthritis. 7 Ultrasmall particles of iron oxide (USPIOs) have been proposed as molecular markers as these particles are phagocytosed by macrophages recruited during the inflammatory process. 3,6,8 -10 This approach is, however, limited in sensitivity and specificity due to the lack of a specific target. An alternative and promising approach is to develop MR contrast agents that are selectively targeted at receptors involved in the inflammatory process. [11] [12] [13] Several cell adhesion molecules are overexpressed on leukocytes and endothelial cells during the inflammatory process. 14 Among these molecules, endothelial selectin (E-selectin) mediates the "slow rolling" of leukocytes in blood by encouraging adhesion to the vascular endothelium. This adhesion process provides the first step of granulocyte, monocyte, and T lymphocyte recruitment toward an inflamed site. 15, 16 De novo E-selectin expression is stimulated by proinflammatory cytokines, like tumor necrosis factor (TNF)-␣ or interleukin-1␤. 11, 16 The up-regulation of E-selectin lasts from 4 to 30 hours after induction of inflammation and can be used as an early marker of inflammation. 15 The natural ligand of Eselectin is the tetrasaccharide, sialyl Lewis X (sLeX). 17 This carbohydrate structure is linked to certain leukocyte surface proteins by specific glycosylation enzymes. 18 In the present study, multimodal molecular approach, with MRI and electron paramagnetic resonance (EPR) using a mimetic of the sLeX molecule coupled to a USPIO, was used to detect inflammation. This mimetic has previously been coupled with other magnetic reporters, such as gadolinium complexes, and successfully used to detect inflammation. 5, 19, 20 USPIOs directed against Eselectin have been proposed recently, using a coating functionalized with antibodies against E-selectin 21 or with the sLeX mimetic molecule. 22 In this study, we coupled the sLeX mimetic on USPIOs that were also coated with the hydrophilic polyethylene glycol (PEG) polymer to prolong the plasma circulation time and minimize the nonspecific accumulation of iron oxide in tissues. [23] [24] [25] The functionalized particles were characterized for their relaxometry properties and their hydrodynamic size. The ability of these functionalized particles to detect inflammation was evaluated in an in vivo model of local inflammation in muscle induced by injection of Freund's complete adjuvant (local stimulation of TNF␣ production). The quantitative detection of iron oxide particles in the tissues was carried out ex vivo using EPR spectroscopy. Finally, the efficacy of the targeted MR contrast agent was evaluated using in vivo EPR spectroscopy and T 2 -weighted imaging.
MATERIALS AND METHODS

Synthesis of the Contrast Agent, USPIO-PEG-sLeX
USPIO-PEG750-sLeX was prepared from nanoparticles with carboxylated groups on their surface (previously described in Reference 26). The USPIOs were modified in 2 successive steps ( Fig.  1) : First, the USPIOs were grafted with the mimetic of the sLeX molecule; 27 second, they were coupled to aminoPEG 750 (Fluka, Bornem, Belgium).
Briefly, 10 mg of the sLeX mimetic and 6 mg of N-(3-Dimethylaminopropyl)-NЈ-ethylcarbodiimide hydrochloride were added to 15 mL of nanoparticles (͓Fe͔ ϭ 0.175 M), and the mixture was stirred overnight. The nanoparticle suspension was ultrafiltered on a 30-kD membrane. AminoPEG750 (0.503 g) and ethylcarbodiimide hydrochloride (0.327 g) were added to the nanoparticles and the reaction was stirred for 17 hours. The mixture was ultrafiltered on a 30 kD membrane to remove low-molecular weight material.
Characterization of the USPIO-PEG-sLeX
Hydrodynamic size was measured by photon correlation spectroscopy on a Brookhaven system BI-160 (New York) equipped with a He-Ne laser ( ϭ 633 nm, 35 mW), a goniometer, and a correlator BI-9000AT-BC. The Nuclear Magnetic Relaxation Dispersion (NMRD) profile was recorded at 37°C on a Fast Field Cycling Relaxometer (Stelar, Mede, Italy). Longitudinal relaxivities were measured over a magnetic field range from 0.24 mT to 0.24 T. The data obtained at 0.5 and 1.5 T were measured with Minispec PC-20 and Mq 60 Series systems (Bruker, Karlsruhe, Germany). The magnetization curve was recorded on a VSM-NUVO magnetometer (MOLSPIN, Newcastle Upon Tyne, UK).
Inflammatory Model
Freund's complete adjuvant was obtained from Sigma-Aldrich (Schnellendorf, Germany). FCAs are water-in-mineral oil emulsions (W/O emulsions) containing heat-killed mycobacteria (Mycobacterium tuberculosis, H34Ra, ATCC25177) at 1 mg/mL.
Animals and Protocol
Male NMRI mice (20 -25 g ) were provided by Janvier (France). For all experiments 5 to 6 mice were used per group. FCA (50 uL) was injected intramuscularly into the right rear leg (gastrocnemius muscle) of mice to stimulate E-selectin expression. 28 The left, noninflamed muscle served as control muscle. Twenty-four hours after induction of inflammation, the USPIO-PEG-sLeX or the ungrafted USPIO-PEG was injected intravenously into a tail vein at a dose of 7.7 mg Fe/kg body weight. The animal protocols were approved by the ethical committee of the Université catholique de Louvain. All experiments were conducted according to national animal care regulations.
Some commercial iron oxide particles were also studied to assess the influence of their size and coating on their kinetics. We used 3 types of preparation: ferumoxide (Guerbet; mean particle size: 80 -150 nm, coating: dextran), ferucarbotran (Schering; mean particle size: 60 nm, coating: carboxydextran), and ferumoxtran-10 (Guerbet; mean particle size: 20 -40 nm, coating: dextran). Each preparation was injected intravenously (7.7 mg Fe/kg) in mice. Mice were killed at different time points (5 minutes, 30 minutes, 1 hours, 2 hours, 3 hours, 5 hours, 18 hours, and 24 hours) and the iron concentrations in blood, liver, and spleen were measured by X-band EPR as described for the USPIO-PEG-sLeX.
Histology
Muscles were sampled 1, 3, and 5 hours after FCA administration, and on days 1, 3, and 7. Two mice were used for each time interval. The mice were killed by cervical dislocation, and the muscle was carefully removed. For comparison, the left gastrocnemius muscle of each mouse served as control. Muscle specimens were fixed in 10% neutral buffered formalin for 24 hours, and then embedded in paraffin. Tissues were sectioned at 5 m and the slides were stained with hematoxylin-eosin. Analyses were performed on an optical microscope (Nikon Alphashot-2 Y52).
Ex Vivo EPR
Twenty-four hours after induction of inflammation, iron oxides were injected into the tail vein of the mice. Blood was collected by retro-orbital puncture and afterward the animals were immediately killed by cervical dislocation (time delays: 1, 3, and 6 hours). The liver, spleen, and both muscles (inflamed and control muscle) were excised. The liver and spleen samples were homogenized in NaCl 0.9% (5 times dilution). The tissue homogenates were aspirated into a Teflon capillary (5 cm long and 0.625 mm diameter), and inserted into a quartz tube that passed through the EPR cavity. As muscles cannot be homogenized easily, the muscle samples were freeze-dried, and the lyophilisate was crushed to obtain a fine powder. A Bruker EMX X-band spectrometer was used for all measurements. The instrument settings were: Fixed excitation frequency, 9.4 GHz; microwave power, 5 mW; modulation field, 100 kHz; center field, 3150 G; field width, 5000 G; modulation amplitude, 30.81 G; conversion time, 20.48 milliseconds; time constant, 20.48 milliseconds; 4096 data points and a total acquisition time of 84 seconds. Measurements were performed at room temperature. Calibration curves (using aqueous suspensions or solid material) were built with known amounts of iron oxide particles. The calibration curve for an aqueous suspension of USPIO-PEG-sLeX is shown in Figure 2 .
In Vivo EPR
In vivo EPR spectra were recorded using an EPR spectrometer (Magnettech, Berlin, Germany) equipped with a low frequency microwave bridge operating at 1.2 GHz and an extended loop resonator. Twenty-four hours after FCA injection, anesthesia was induced using 3% isoflurane (in air), and then maintained using 1.8% isoflurane. USPIO-PEG-sLeX or nongrafted USPIO-PEG were injected into the tail vein. The muscles were inserted into the loop resonator, keeping the same position for all mice. In vivo EPR spectra were recorded at 1, 2, 3, and 4 hours under the following conditions: Fixed excitation frequency, 1.2 GHz; microwave power, 24 mW; modulation field, 100 kHz; center field, 53 mT; field width, 20 mT; modulation amplitude, 0.42 mT; 1024 data points and a total acquisition time of 60 seconds. 
In Vivo MRI
Twenty-four hours after FCA injection, the animals were anesthetized with isoflurane (3% induction, 1.8% maintenance). MR images were obtained on a Bruker BIOSPEC system equipped with a horizontal 4.7 T magnet. The images were acquired using a T 2 -weighted RARE sequence. The parameters were repetition time, TR ϭ 3.2 seconds; echo time, TE, 66.9 milliseconds; bandwidth, 50 kHz; FOV, 5 cm; matrix size, 128 ϫ 128; 2-mm slice thickness; acquisition time, 6 minutes 49 seconds. After a precontrast sequence, USPIO-PEG-sLeX or nongrafted USPIO-PEG were injected into the tail vein of the mice. Postcontrast images of the muscles were acquired at different time delays (every 30 minutes until 3 hours) after injection of the iron oxides. As a control, we placed a phantom tube containing CuSO 4 (100 mg/L) alongside the animals and measured the phantom signal before and after the contrast media injection. For the analysis, Paravision software was used to measure the signal intensities (SI) in the different regions of interest chosen in the control muscle, the inflamed muscle, and the phantom. Muscle SI was normalized to the SI of the phantom, yielding a relative intensity (RI) for each muscle. Negative contrast enhancement values were calculated for each time point using the following equation:
% enhancement values ϭ (͓RI post Ϫ RI pre͔)/RI pre) ϫ 100.
For MRI data analysis the T 2 relaxation time has been calculated from the multispin-echo datasets using in-house software based on the interactive data language (Research Systems, Boulder, CO). Regions of interest were drawn within the inflamed tissue and the mean T 2 value was calculated before and after contrast-enhancement of the inflamed muscles to evaluate the T 2 shortening produced by the grafted or ungrafted USPIO particles.
Statistical Analysis
All results are given as mean values Ϯ SEM from 5 to 6 animals per group. Comparisons between groups were made with Student 2-tailed t test and a P Ͻ 0.05 was considered as significant. The following symbols are used in the figures: *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001.
RESULTS
Characterization of the USPIO-PEG-sLeX
The hydrodynamic size of the synthesized USPIO-PEG-sLeX was 23 nm (polydispersity index ϭ 0.128). The R 1 -NMRD profile of USPIO-PEG-sLeX is shown in Figure 3 
. The relaxivity is defined as relaxation rate of water protons in 1 mmol/L solution of contrast agents and its value is expressed in mmol/L in iron. Interpretation of the relaxation profiles (ie, evolution of the relaxivity as a function of the magnetic field) with appropriate theoretical models 29, 30 provides information about the main properties of the superparamagnetic crystals, such as their specific magnetization (51.7 Am 2 /kg) and their size (d ϭ 11.6 nm). The corresponding values obtained by magnetometry (Fig. 3, right) were Ms ϭ 68.3 Am 2 /kg for the magnetization and d ϭ 9.8 nm for the crystal diameter. As previously observed, the mean diameter obtained by magnetometry was less than that obtained by relaxometry. This difference can be explained by a distribution of crystal sizes, which influences the mean size obtained by the various methods. 31 This size dispersion is also responsible for the lower specific magnetization obtained by relaxometry compared with that obtained by magnetometry.
Inflammatory Model
Histologic analysis confirmed the presence of a large area of inflammation in the muscle injected with FCA. Inflammatory cells were recruited near the site of injection which was identified by remaining droplets of mineral oil. Inflammatory cell recruitment was already visible 1 hour after administration of FCA, increased progressively up to 1 day after injection, and then remained unchanged on days 3 and 7. A typical histologic image (obtained 1 day after injection of FCA) is shown in Figure 4 . As it was established that E-selectin is highly up-regulated in this inflammatory model, 28 and as the up-regulation lasts from 4 to 30 hours after induction of the inflammation, we further used 24 hours after injection of FCA to evaluate the distribution of the USPIOs.
Ex Vivo EPR
USPIOs exhibit an EPR spectrum, which directly reflects the number of iron oxide particles in a sample (Fig. 2) . EPR spectroscopy has already been proposed as a method of quantifying the accumulation of iron oxide inside tissues. 32 Calibration curves were built from saline and liver homogenates containing known concentrations of iron oxide particles. The calibration curves did not change when the particles were dispersed in saline or in liver homogenates (data not shown). The EPR spectra were characterized by an average g value of 2.13. Typical EPR spectra recorded in different tissues (blood, spleen, and liver) are shown in Figure 5 . The evolution of the concentration of USPIO-PEG-sLeX in different tissues is shown in Figure 6 . In blood (Fig. 6, left) , we observed a decrease in circulating USPIO-PEG-sLeX over time. The iron oxide remaining in the circulation 1 hour after IV injection, expressed as a percentage of the initial blood concentration just after injection, was 17.7% Ϯ 0.7% for USPIO-PEG-sLeX and 17.5% Ϯ 0.8% for USPIO-PEG (mean Ϯ SEM, n ϭ 5). Under the same conditions, the remaining circulating iron oxides were 4.7% Ϯ 0.4%, 2.7% Ϯ 0.2%, and 0.9% Ϯ 0.1% of the initial blood concentration for ferumoxtran-10, ferucarbotran, and ferumoxide, respectively. The concentration of USPIO-PEGsLeX was less than 3% after 6 hours, and it was completely cleared from the blood 24 hours after administration (data not shown). In the spleen, the concentration of USPIO-PEG-sLeX reached a plateau by 3 hours after injection and then remained stable for the rest of the observation period (6 hours). In the liver, the concentration of USPIO-PEG-sLeX increased over time, but the rate of accumulation appeared to slow slightly 3 hours after administration. After this preliminary USPIO-PEG-sLeX biodistribution study, we evaluated the inflamed muscles. The results are expressed as a percentage of the iron oxide concentration detected in the noninflamed control muscle (Fig. 7) . The accumulation of iron oxide particles in the inflamed muscle was significantly higher after administration of USPIO-PEG-sLeX compared with ungrafted USPIO-PEG. Three hours after injection of the contrast media, the mean muscular iron content was 561% Ϯ 60% (mean Ϯ SEM, n ϭ 5) for mice injected with USPIO-PEG-sLeX, and 308% Ϯ 18% for mice injected with ungrafted USPIO-PEG. In other words, the iron content was about 6 times higher in the inflamed muscle than in the control muscle, using USPIO-PEG-sLeX, and when using USPIO-PEG control particles, iron concentration is still 3 times higher in inflamed muscles than in control muscles. The amount of iron accumulated in the inflamed muscle was about 0.8% of the injected dose when using USPIO-PEG-sLeX compared with 0.4% obtained with USPIO-PEG particles.
In Vivo EPR
Using EPR spectrometers operating at low frequency, it is possible to record EPR spectra directly in vivo. We looked at the feasibility of detecting USPIO directly in vivo using these systems. Interestingly, the EPR signal was easily visible in inflamed muscles, (Fig. 8, left) . The SI was measured as a function of time (Fig. 8, right) . Between 3 and 4 hours after the injection, the SI recorded in the inflamed muscle was twice as high with USPIO-PEG-sLeX as with ungrafted USPIO-PEG.
In Vivo MRI
Iron oxide particles are characterized by a large magnetic moment and a large size that leads to a shortening of the transverse relaxation time (T 2 ) and to considerable signal loss in T 2 -weighted MRI sequences. MR images were obtained before and at different times following the intravenous administration of iron oxide particles (Fig. 9, left) . The SI decreased rapidly in the inflamed muscle after administration of USPIO-PEG-sLeX. The signal loss was Ϫ49% Ϯ 4% 60 minutes after the administration of the contrast agent, and remained stable until the end of the 3 hours imaging period (Ϫ54% Ϯ 4%). The decrease in SI was less pronounced when using the ungrafted USPIO-PEG (Ϫ36% Ϯ 4%). There was also a small, but significant, decrease in SI in the control muscle (around 10%) after injection of both contrast media.
Calculated T 2 values were obtained from mice before and 3 hours after administration of either USPIO-PEG-sLeX or USPIO-PEG. The shortening of the transversal relaxation time T 2 in inflamed mice muscle is about 41.8 Ϯ 5.2 milliseconds when targeted particles were injected and only 21.1 Ϯ 5.1 milliseconds for the untargeted ones (Fig. 10) . Compared with the T 2 value measured on precontrast images the particles produce a T 2 shortening of 62.9% and 37.3%, respectively, which kind of reconfirms the percentages obtained for the negative signal enhancement.
DISCUSSION
The major insights of the present study are (a) EPR and MRI can be used complementarily to assess the amount and localization of targeted iron oxide particles; (b) USPIO-PEG-sLeX accumulate preferentially in inflamed areas, and may be used as inflammationselective MR contrast agents.
Multimodality approach involves the incorporation of at least 2 measuring modalities using labeled "reporter" agents. Useful complementary information coming from a multimodal approach may be related to localization (macroscopic imaging or histology), absolute quantification, metabolism, or gene activation. NMR spectroscopy and imaging are able to provide important anatomic, functional, and metabolic imaging, with very high spatial resolution for several nuclei. To measure real concentrations of iron oxide in tissues, other authors have used the incorporation of radioactive 59 Fe in the USPIO core 33 or inductively coupled plasma-atomic emission spectrometry. 34 Here, we used EPR, a magnetic resonance method that detects the presence of species carrying unpaired electrons with high sensitivity. EPR spectrometry is interesting because it is more sensitive than NMR (due to the difference in gyromagnetic ratio) and because the EPR signal intensity quantitatively reflects the amount of iron oxide particles, without any confounding effect. Calibration curves were built with standard amounts of iron oxide contrast agent to check the linearity of the response (Fig. 2) . EPR is generally used in vitro or ex vivo on freeze-dried samples or thin tissue homogenates to avoid the dielectric loss observed in large aqueous samples. Early work carried out on magnetite particles in the nineties indicated that X-Band EPR was useful to monitor the clearance of iron oxide particles from the blood 32 and their accumulation in the liver and in the spleen by ex vivo sampling. 35 To correlate the dynamics observed in MRI with EPR, we also used a low frequency EPR spectrometer (1GHz) that allows a wave penetration of 1 cm inside tissue, which was typically the size of the muscles analyzed in the present study. To our knowledge, only one in vivo study has reported the detection of superparamagnetic iron oxide particles in the liver using an L-band spectrometer. 36 So far, EPR has never been used in the evaluation of targeted iron oxide particles developed for molecular imaging.
To conduct a fair comparison between USPIO-PEG-sLeX and USPIO-PEG, we first checked the EPR and NMR characteristics of both iron oxide contrast agents. The r 2 relaxivities obtained for USPIO-PEG-sLeX are comparable to values obtained previously with ungrafted USPIO-PEG or USPIO grafted with sLeX without pegylation of the particles. 22 This finding confirms that the branching did not induce a major change in the relaxometric properties of these compounds. We also observed that the EPR signal intensity and shape were not dependent on the coating of the surface of the particle, nor on the tissue in which the USPIO was dispersed. This observation allowed us to quantify and compare directly the content of the contrast agent in different tissues.
The change in blood clearance as a result of the branching of PEG polymers at the surface of the particles is obvious when the amount of iron oxide particles remaining in the circulating blood is compared for different preparations. Comparison with ferumoxtran-10 is the most relevant as this compound has a size (20 -40 nm) comparable to that of USPIO-PEG-sLeX (23 nm). One hour after administration, the blood concentration of USPIO-PEG-sLeX (and of the ungrafted USPIO-PEG) was about 4 times higher than the blood concentration of ferumoxtran-10. The PEG chains, which are known to reduce plasma protein binding (opsonization), do indeed delay clearance by macrophages. It should be noted that the pegylation did not preclude the final accumulation of USPIOs in the reticulo-endothelial system as we observed a large uptake by the liver and the spleen (Fig. 6) . Nevertheless, the increased half-life in the blood is beneficial to the possible molecular recognition of targeted sites.
To estimate the ability of USPIO-PEG-sLeX to specifically detect local inflammation, we used ex vivo EPR, in vivo EPR and MRI. Ex vivo EPR allowed the absolute quantification of iron oxide particles in tissues by comparison with standard calibration curves (Fig. 2) . Interestingly, we obtained in vivo EPR signals from USPIOs with a high signal-to-noise ratio using rapid scans (1 minute) in a noninvasive manner. It should be emphasized that the absolute quantification by EPR is theoretically more difficult to obtain in vivo than ex vivo, as the signal strongly depends on the geometry of detection. However, we obtained a reasonable quantification by carefully placing the leg muscle in exactly the same position from one study to another. The results obtained by both techniques (Figs. 7, 8 ) are remarkably concordant. Finally, MRI studies were carried out to evaluate the ability of this new contrast agent to improve the contrast in inflamed tissues. The 3 methods led to the same conclusions: (1) the ungrafted USPIO-PEG was more concentrated in inflamed muscles than in control muscles; (2) there was a higher accumulation (by a factor 2) of USPIO-PEG-sLeX compared with ungrafted USPIO-PEG in inflamed areas. The large concentration of ungrafted USPIO-PEG in inflamed muscles as compared with control muscles can be explained by the fact that inflamed muscle will recruit a large number of macrophages. These macrophages will take up USPIOs in a nonspecific manner. Furthermore, inflammation causes vasodilation and increased vascular permeability. The resulting improvement in blood flux and transendothelial passage enables a greater accumulation of iron oxide particles in the inflamed tissue. Even taking into account the nonspecific accumulation of USPIOs in local macrophages, our results clearly indicate that the use of USPIO-PEG-sLeX improved the ability to detect inflammation by a factor of 2 compared with ungrafted USPIO-PEG.
In conclusion, USPIO-PEG-sLeX shows promise as an in vivo tool for the noninvasive analysis of the expression of E-selectin in different disorders. The long intravascular persistence time, selective accumulation in inflamed tissues, and the high and prolonged contrast provided in MRI studies support further studies using this new type of contrast agent.
